stockrowLigand Pharmaceuticals Incorporated
LGND Healthcare Biotechnology
Ligand Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $268.1 million, up 60.4% from fiscal 2024.
- Revenue
- −31.8%
- EPS
- −123.9%
- Free cash flow
- −268.5%
- Total debt
- +52.6%
Quarter to September 2026, against a year earlier
Follow LGND
Alert me
Ligand Pharmaceuticals Incorporated (LGND) Total debt
Ligand Pharmaceuticals Incorporated's total debt at the end of fiscal 2025 was $446.2M, up 414.7% from $86.7M in fiscal 2022. At the end of the quarter to 30 September 2026 it was $679.9M. Over the past ten years it has ranged from $86.7M (fiscal 2022) to $640.0M (fiscal 2019); the current reading is higher than 67% of that period. Ligand Pharmaceuticals Incorporated ranks 22nd of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $446.2M | 414.67% |
| FY2022 | $86.7M | (73.05%) |
| FY2021 | $321.7M | (28.55%) |
| FY2020 | $450.3M | (29.64%) |
| FY2019 | $640.0M | 0.58% |
| FY2018 | $636.3M | 161.43% |
| FY2017 | $243.4M | 0.38% |
| FY2016 | $242.5M | 0.36% |
| FY2015 | $241.6M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $679.9M | (39.65%) |
| Jun 2026 | $1.1B | 152.09% |
| Mar 2026 | $446.9M | 0.16% |
| Dec 2025 | $446.2M | 0.16% |
| 36 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | $2.8B |
| IONS Ionis Pharmaceuticals, Inc. compare | $1.4B |
| MIRM Mirum Pharmaceuticals, Inc. compare | $731.3M |
| LGND Ligand Pharmaceuticals Incorporated | $679.9M |
| KOD Kodiak Sciences Inc. compare | $174.5M |
| CGON CG Oncology, Inc. compare | $3.0M |
| IMVT Immunovant, Inc. compare | $614.0K |
| ORKA Oruka Therapeutics, Inc. compare | $301.0K |
| BLTE Belite Bio, Inc. Sponsored ADR compare | — |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on LGND
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement